Pharming Technologies Completes Cash Offer for Abliva
Pharming Technologies B.V. has successfully concluded its unconditional cash offer to acquire Abliva AB (publ), marking a significant milestone for both companies in the biopharmaceutical sector. This strategic move has implications for shareholders and sets the stage for future advancements in drug development.
The Unconditional Cash Offer
On December 15, Pharming Technologies, a fully owned division of Pharming Group N.V., initially disclosed a cash offer to Abliva shareholders, proposing a purchase price of SEK 0.45 per share. Following the formalities, an offer document was released on January 15, 2025, detailing the conditions of the offer.
Shareholder Acceptance Rate
As of the conclusion of the acceptance period, which was officially on February 7, shareholders holding a total of 1,413,841,472 shares—approximately 87.7% of Abliva’s total equity—accepted the offer. This overwhelming approval underlines the confidence shareholders have in Pharming’s vision and plans.
Changes to Offer Conditions
In a recent announcement, the company indicated its decision to waive the acceptance level condition that required ownership of more than 90% for completion of the offer. With all other completion conditions satisfied, Pharming is ready to proceed with acquiring all the shares tendered up to February 7, 2025, with settlements expected to commence shortly after.
Extended Acceptance Period for Remaining Shareholders
To accommodate those shareholders who have yet to accept the offer, Pharming has extended the acceptance period to February 20, 2025, at 15:00 CET. For shareholders who participate during this extended time frame, settlements are expected to start around February 27, 2025. This extension is a clear indication of Pharming’s commitment to engaging with all shareholders and ensuring a smooth acquisition process.
Warrants and Shareholder Rights
The offer notably excludes the warrants issued by Abliva to its employees and board members under its incentive programs. Pharming has proactively engaged with these warrant holders to secure the rights to acquire the warrants as part of the deal. The pricing for these warrants has been determined considering standard valuation methodologies, ensuring fairness in the acquisition process.
Future Implications for Abliva Shareholders
Now that the offer is unconditional, shareholders who have accepted or are willing to accept the offer can no longer withdraw their acceptances. This decision reinforces the certainty of the transaction and paves the way for Pharming to initiate a compulsory acquisition process if it eventually owns 90% of Abliva’s shares.
Strategic Vision and Corporate Goals
With headquarters in Leiden, Netherlands, Pharming Group N.V. focuses on developing innovative therapies for rare diseases, emphasizing protein replacement therapies. The successful acquisition of Abliva aligns with Pharming’s growth objectives and enhances its capabilities in providing life-changing treatments to patients worldwide. The integration of Abliva's assets is anticipated to expand Pharming’s portfolio and strengthen its market presence.
Communication and Contact Information
For any inquiries regarding the acquisition or details about the ongoing processes, stakeholders can reach out to Pharming Group directly. Their investor relations department, headed by Michael Levitan, remains available for further engagement. Additionally, shareholder communication regarding the deal will be disseminated widely, ensuring transparency and clarity throughout the process.
Frequently Asked Questions
What is the significance of Pharming's acquisition of Abliva?
This acquisition enhances Pharming's portfolio in the rare diseases market, allowing them to leverage Abliva's assets for increased growth and innovation.
What happens to shareholders who accept the offer?
Once shareholders accept the offer, they can no longer withdraw their acceptances, signifying that the acquisition process will continue unhindered.
How does the extension of the acceptance period affect shareholders?
The extension provides additional time for those who have yet to decide, ensuring that all shareholders have the opportunity to participate in the offer.
Will Pharming acquire any warrants from Abliva?
Yes, Pharming has negotiated to acquire the warrants held by Abliva’s employees and board members, ensuring a fair offer based on standard valuation practices.
What will Pharming do with Abliva shares after the acquisition?
If Pharming reaches a 90% ownership threshold, they may initiate a compulsory acquisition procedure to fully integrate Abliva into their operations, potentially leading to a delisting from Nasdaq Stockholm.
